This is a planned single center prospective randomized study evaluating the safety and
efficacy of low dose thymoglobulin as induction agent in renal transplant recipients.
Inclusion criteria will be adult renal transplant recipients who are not sensitized against
their potential donors. The patients who agree to participate in the study will be randomly
assigned to either thymoglobulin at 1.25mg/kg x 3 doses or 0.75mg/kg x 3 doses. There will be
86 sealed envelopes to perform the randomization process. 43 envelopes with 1.25mg/kg dosing
and the other 43 envelopes with 0.75mg/kg dosing. The investigators will sequentially choose
the sealed envelopes at the time of the patient randomization process. All patients will be
started on our standard immunosupression regimen of prograf/cellcept and a fast steroid
taper. Data will be obtained from every patient for up to one year post-transplant.